Last reviewed · How we verify
sufficient dose of rocuronium
Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate, causing muscle paralysis.
Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate, causing muscle paralysis. Used for Facilitation of endotracheal intubation during anesthesia induction, Maintenance of neuromuscular blockade during general anesthesia and mechanical ventilation.
At a glance
| Generic name | sufficient dose of rocuronium |
|---|---|
| Also known as | sugammadex at the end of surgery |
| Sponsor | Korea University Guro Hospital |
| Drug class | Non-depolarizing neuromuscular blocking agent |
| Target | Nicotinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Rocuronium binds to nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and triggering muscle contraction. This results in flaccid paralysis of skeletal muscles. The drug is used during anesthesia to facilitate intubation and maintain muscle relaxation during surgery.
Approved indications
- Facilitation of endotracheal intubation during anesthesia induction
- Maintenance of neuromuscular blockade during general anesthesia and mechanical ventilation
Common side effects
- Prolonged neuromuscular blockade
- Histamine release (flushing, hypotension, tachycardia)
- Anaphylaxis
- Postoperative residual curarization
Key clinical trials
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Comparison of Peri-intubation Oxygenation Values and Complications in Patients Intubated With the Delayed Versus Rapid Sequence Intubation Protocols (NA)
- Inhalational Agents Versus Dexmedetomidine for Maintenance of General Anesthesia (NA)
- Two Video Laryngoscopes (Laringocel® and C-MAC®) for First-Attempt Intubation in Adults Undergoing Elective Surgery (NA)
- The Effect of Sedoanalgesia and General Anaesthesia on Early Neurological Recovery in Acute Ischaemic Stroke Patients Undergoing Endovascular Thrombectomy (NA)
- Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes (NA)
- Comparative Analysis of Spinal Anesthesia Versus General Anesthesia for vNOTES (NA)
- Venous Cannulation Pain to Guide Choice of Anesthetic Method (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sufficient dose of rocuronium CI brief — competitive landscape report
- sufficient dose of rocuronium updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI